Beam Therapeutics, Inc. ((BEAM)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Beam Therapeutics, Inc. is conducting a Phase 1/2 study titled ‘A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease.’ The study aims to assess the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and efficacy of BEAM-302, as well as to determine the optimal biological dose (OBD) for treating AATD-associated conditions.
Intervention/Treatment: The intervention being tested is BEAM-302, a lipid nanoparticle (LNP)-based therapy designed to treat patients with Alpha-1 Antitrypsin Deficiency (AATD).
Study Design: This is an interventional study with a single-group assignment model. There is no masking involved, meaning both researchers and participants know the treatment being administered. The primary purpose of the study is treatment-focused.
Study Timeline: The study began on April 22, 2024, with the latest update submitted on June 9, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data being collected.
Market Implications: The ongoing study of BEAM-302 could significantly impact Beam Therapeutics’ stock performance, as positive results may enhance investor confidence and market value. Given the competitive landscape in genetic therapies, advancements in this study could position Beam Therapeutics favorably against competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.